CSL is a leading global biotech company delivering innovative therapies to help people with life-threatening conditions live full lives.
The CSL Research Acceleration Initiative supports early-stage biotechs and research organizations to fast-track the discovery of groundbreaking biotherapies.
Successful applicants can receive up to $400,000 USD in non-dilutive funding over 2 years to advance their innovative programs.
Interested researchers are invited to:
- Attend an information webinar (choose one of two sessions)
Tuesday, 20 January 4:00PM CET (UTC+1) – Click to join
Tuesday, 3 February 11:00AM CET (UTC+1) – Click to join
- Submit enquiries, expressions of interest and requests for application instructions to: RAI@CSL.com.au
- Submit a non-confidential, 500-word abstract via the CSL online application portal by 24th February2026.
The 2026 Research Acceleration Initiative will focus on research proposals that align with a CSL Therapeutic Area.
- Transplant & Immunology
- Cardiovascular & Renal
- Hematology
- Immunoglobulins
- Oral Delivery
Please find here more information for specific Focus Areas.
CSL is also interested in new uses for our existing products. If you have a proposal in this area, please e-mail to discuss.
For additional information or enquiries, please reach out to: RAI@CSL.COM.AU